BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 37526935)

  • 21. [Role of 18FDG-PET/CT in the management and gross tumor volume definition for radiotherapy of head and neck cancer; single institution experiences based on long-term follow-up].
    Hideghéty K; Cserháti A; Besenyi Z; Zag L; Gaál S; Együd Z; Mózes P; Szántó E; Csenki M; Rusz O; Varga Z; Dobi Á; Maráz A; Pávics L; Lengyel Z
    Magy Onkol; 2015 Jun; 59(2):103-10. PubMed ID: 26035157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST.
    Katsuura T; Kitajima K; Fujiwara M; Terada T; Uwa N; Noguchi K; Doi H; Tamaki Y; Yoshida R; Tsuchitani T; Fujita M; Yamakado K
    Ann Nucl Med; 2018 Aug; 32(7):453-462. PubMed ID: 29858797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
    Suenaga Y; Kitajima K; Ishihara T; Sasaki R; Otsuki N; Nibu K; Minamikawa T; Kiyota N; Sugimura K
    Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PET/CT prior to salvage surgery in recurrent head and neck squamous cell carcinoma.
    Nøhr A; Gram SB; Charabi B; Tvedskov JF; Wessel I; Friborg J; Håkansson K; von Buchwald C; Fischer BM; Rasmussen JH
    Eur Arch Otorhinolaryngol; 2019 Oct; 276(10):2895-2902. PubMed ID: 31297609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Utility of Pretreatment and 3-Month
    Mayo Z; Seyedin SN; Mallak N; Mott SL; Menda Y; Graham M; Anderson C
    Ann Otol Rhinol Laryngol; 2019 Jul; 128(7):595-600. PubMed ID: 30808209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Should PET/CT be implemented in the routine imaging work-up of locally advanced head and neck squamous cell carcinoma? A prospective analysis.
    Cacicedo J; Fernandez I; Del Hoyo O; Dolado A; Gómez-Suarez J; Hortelano E; Sancho A; Pijoan JI; Alvarez J; Espinosa JM; Gaafar A; Bilbao P
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1378-89. PubMed ID: 25952280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between hematological parameters and PET/CT metabolic parameters in patients with head and neck cancer.
    Bojaxhiu B; Sinovcic D; Elicin O; Templeton AJ; Shelan M; Wartenberg J; Alberts I; Rominger A; Aebersold DM; Zaugg K
    Radiat Oncol; 2022 Aug; 17(1):141. PubMed ID: 35964056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-treatment
    Jung AR; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2020 Aug; 107():104750. PubMed ID: 32361565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic performance of
    Chaput A; Robin P; Podeur F; Ollivier M; Keromnes N; Tissot V; Nonent M; Salaün PY; Rousset J; Abgral R
    Laryngoscope; 2018 Feb; 128(2):378-385. PubMed ID: 28600822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of quantitative imaging parameters in head and neck squamous cell carcinoma.
    Gupta T; Chatterjee A; Rangarajan V; Purandare N; Arya S; Murthy V; Budrukkar A; Ghosh-Laskar S; Agarwal JP
    Q J Nucl Med Mol Imaging; 2022 Jun; 66(2):162-170. PubMed ID: 31496204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of subclinical recurrence or second primary cancer using (18) F-FDG PET/CT in patients treated curatively for head and neck squamous cell carcinoma.
    Kikuchi M; Shinohara S; Hino M; Itoh K; Tona R; Kishimoto I; Harada H; Fujiwara K; Suehiro A; Naito Y
    Head Neck; 2016 Apr; 38 Suppl 1():E511-8. PubMed ID: 25783743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upfront PET/CT affects management decisions in patients with recurrent head and neck squamous cell carcinoma.
    Rohde M; Nielsen AL; Johansen J; Sørensen JA; Diaz A; Pareek M; Asmussen JT; Gerke O; Thomassen A; Gyldenkerne N; Døssing H; Bjørndal K; Høilund-Carlsen PF; Godballe C
    Oral Oncol; 2019 Jul; 94():1-7. PubMed ID: 31178202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The response rate of PET-CT in the follow-up of head and neck squamous cell carcinoma patients.
    Laus M; Festa Kotelnikova E; Cazzato F; Buonamico A; Croce A
    Minerva Surg; 2022 Oct; 77(5):481-487. PubMed ID: 35230034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years.
    Paidpally V; Tahari AK; Lam S; Alluri K; Marur S; Koch W; Wahl RL; Subramaniam RM
    J Nucl Med; 2013 Dec; 54(12):2039-45. PubMed ID: 24101687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma.
    Abgral R; Le Roux PY; Keromnes N; Rousset J; Valette G; Gouders D; Leleu C; Mollon D; Nowak E; Querellou S; Salaün PY
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1839-47. PubMed ID: 22895863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre-CCRT 18-fluorodeoxyglucose PET-CT improves survival in patients with advanced stages p16-negative oropharyngeal squamous cell carcinoma via accurate radiation treatment planning.
    Chen TM; Chen WM; Chen M; Shia BC; Wu SY
    J Otolaryngol Head Neck Surg; 2023 Feb; 52(1):14. PubMed ID: 36782296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of clinical and
    Cho JK; Hyun SH; Choi JY; Choi N; Kim MJ; Lee SH; Baek KH; Jeong HS
    J Surg Oncol; 2016 Dec; 114(7):888-894. PubMed ID: 27546387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of (18)F-FDG PET/CT staging on management and prognostic stratification in head and neck squamous cell carcinoma: A prospective observational study.
    Ryu IS; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Eur J Cancer; 2016 Aug; 63():88-96. PubMed ID: 27288873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [
    Vos JL; Zuur CL; Smit LA; de Boer JP; Al-Mamgani A; van den Brekel MWM; Haanen JBAG; Vogel WV
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2010-2022. PubMed ID: 34957526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical utility of
    Ha SC; Roh JL; Kim JS; Lee JH; Choi SH; Nam SY; Kim SY
    Acta Otolaryngol; 2019 Sep; 139(9):810-815. PubMed ID: 31274365
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.